

Question Paper

Exam Date & Time: 19-May-2023 (10:00 AM - 01:00 PM)



MANIPAL ACADEMY OF HIGHER EDUCATION

Pharmacovigilance [PPR-BP805ET -S3]

Marks: 75

Duration: 180 mins.

I Multiple Choice Questions (MCQs)

Answer all the questions.

Section Duration: 30 mins

- 1) Adverse Drug Reactions, that are pharmacologically related and dose-dependent are categorized as ----- (1)

[Type A](#)

[Type B](#)

[Type](#)

[C](#)

[Type](#)

[D](#)

- 2) Pharmacovigilance is a branch of science including activities related to, (1)

[Detection, control, and prevention of adverse drug reactions](#)

[Detection, control, and prevention of adverse drug reactions](#)

[Detection, evaluation, control, and prevention of adverse drug reactions](#)

[Evaluation, Control, and Reporting of adverse drug reactions](#)

- 3) The incidence adverse drug reaction (ADR) of more than 10 percent is called (1)

[Common ADR](#)

[Rare ADR](#)

[Very common](#)

[ADR](#)

[Very rare ADR](#)

- 4) The followings are specific aims of pharmacovigilance, EXCEPT, (1)

[Contribute to the assessment of benefits & harm](#)

[Improve patient care and safety](#)

[Improve public health and safety](#)

[Promote sales and marketing of the drug](#)

- 5) Based on the severity of the adverse drug reaction (ADR), the ADR either directly or indirectly leads to the death of the patient, (1)

[Level](#)

[1](#)

[Level](#)

[3](#)

[Level](#)

[5](#)
[Level](#)
[7](#)

6) According to causality assessment based on modified Naranjo's scale, how many categories of ADRs? (1)

[2](#)
[4](#)
[6](#)
[8](#)

7) A rich and highly specific standardized medical terminology to facilitate sharing of regulatory information internationally for medical products used by humans, (1)

[MedDRA](#)
[MedWatch](#)
[VigiFlow](#)
[VigiLyze](#)

8) Which of the following is not included in the WHO Drug Dictionary (1)

[Herbal remedies](#)
[Vaccine](#)
[Blood products](#)
[Food Products](#)

9) The third level of ATC classification refers to (1)

[Anatomical](#)
[Chemical subgroup](#)
[Chemical substance](#)
[Pharmacological](#)

10) The following causes are vaccine-related vaccine failure, EXCEPT, (1)

[Incomplete coverage of strains](#)
[Vaccine is not 100% efficacious](#)
[Vaccine-vaccine interactions](#)
[Waning immunity](#)

11) "The occurrence of the specific vaccine-preventable disease in a person who is appropriately and fully vaccinated taking into account the incubation period and the normal delay for the protection to be acquired as a result of immunization" is called, (1)

[Confirmed clinical vaccine failure](#)
[Confirmed immunological vaccine failure](#)
[Suspected clinical vaccine failure](#)
[Suspected immunological vaccine failure](#)

12) The national regulatory authority is the agency ensures the following aspects of vaccines, EXCEPT, (1)

[Efficacy](#)
[Promotion](#)
[Quality](#)
[Safety](#)

13) The Cohort studies are generally, (1)

[Prospective](#)

- [Retrospective](#)
[Can be both](#)
[Monitor one time](#)
- 14) Cross-sectional studies, (1)
- [Are not useful for ecological analysis](#)
[Have historic controls](#)
[Outcomes and exposure at the same time](#)
[Select participants without exposure](#)
- 15) The communication between public, and healthcare professionals are different, (1)
- [Public demand both information and transparency. prioritize the benefit-risk balance](#)
[Public demand information and transparency](#)
[Public prioritize the balance between benefit-risk](#)
[None of the above](#)
- 16) Most crises result from, (1)
- [Severe non-compliance to regulations](#)
[Severe non-compliance to established standards](#)
[Severe compliance to fundamental ethical principles](#)
[Both A & B](#)
- 17) Most of the medicines are metabolized by the enzyme, (1)
- [CYP1A2](#)
[CYP2C19](#)
[CYP2C9](#)
[CYP2D6](#)
- 18) Genotoxicity studies should be completed before which of the following Phase of clinical trial ----- (1)

- [Phase 1](#)
[Phase 2](#)
[Phase 3](#)
[Phase 4](#)
- 19) In Drug and Cosmetic Act, schedule X refers ----- (1)
- [Biologicals](#)
[GMP](#)
[Narcotics](#)
[Prescription Drugs](#)
- 20) Approval of a trial protocol and safeguard of rights, safety and well-being of all trial subjects in the clinical trial monitored by ----- (1)
- [CDSCO](#)
[DCGI](#)
[Ethics committee](#)
[Investigator](#)

II Long Answers

Answer all the questions.

- 1) Define adverse drug reactions (ADRs). Discuss the role of pharmacists in monitoring ADRs. (10)
- 2) Explain in detail ICH standards for Post-approval expedited reporting. (10)

III Short Answers

Answer all the questions.

- 1) Describe the structure of ATC system and explain the purpose of ATC/DDD system. (5)
- 2) Write a note on MedRA coding. (5)
- 3) Write a note on Pharmacovigilance in CRO. (5)
- 4) Discuss vaccine life cycle. (5)
- 5) Describe method of cross sectional studies used in ADR monitoring. (5)
- 6) Explain about an ideal communication process. (5)
- 7) Write a note on Drug safety evaluation in pregnancy. (5)

-----End-----